Pipelines

Home > R&D >Pipelines>Protein/Peptide Drug

Place the cursor on the bars to see more details.

LAPSCOVERY  Pipelines
(as of Aug.2011)
Candidates  Characteristics  Indication DevelopmentStage
Research Preclinical  Clinical
I II III
LAPS-Exendin
(HM11260C)		 - Long-acting Exendin-4 analog
- Once monthly administration 		Type II
Diabetes
EU PhaseⅡ/ KR Phase I
  • Dec. 2008. Preclinical started
  • Oct. 2009. KR IND submitted
  • Jan. 2010. KR PhaseⅠstarted
  • Apr. 2010. EU IMPD submitted
  • May. 2010. EU CTA approved
  • May. 2010. EU PhaseⅡ started
LAPS-hGH
(HM10560A)		 - Long-acting hGH
- Once biweekly administration 		Growth
disorder
EU PhaseⅡ / KR PhaseⅠ
  • Aug. 2010. Preclinical started
  • Oct. 2009. KR IND submitted
  • Feb. 2010. KR PhaseⅠstarted
LAPS-GCSF
(HM10460A)		 - Long-acting G-CSF analog
- Once every 3week administration 		Neutropenia
US / KR Phase I
  • Apr. 2008. Preclinical started
  • May. 2009. US IND submitted
  • Jun. 2009. KR IND submitted
  • Sep. 2009. KR Phase I started
  • Nov. 2009. US Phase I started
LAPS-EPO
(HM10760A)		 - Long-acting EPO
- Once monthly administration		 Anemia
US / KR Phase I
  • Jun. 2008. Preclinical started
  • Jun. 2009. KR IND submitted
  • Aug. 2009. US IND submitted
  • Sep. 2009. US & KR Phase I started
LAPS-IFNα
(HM10660A)		 - Long-acting IFNα
- Once weekly administration 		HCV/Cancer
EU Phase I
  • Jul. 2009. Preclinical started
  • Mar. 2011. EU CTA approved
  • Apr. 2011. EU Phase I planned
LAPS-Insulin
(HM12460B) 		- Long-acting Insulin
- Once or Twice a week 		Type II Diabetes
 


Oncology  Pipelines
(as of Aug..2011)
Pipelines Characteristics DevelopmentStage
Research Preclinical  Clinical
I II III
OraxolTM
(Oral Paclitaxel)		 - Paclitaxel +HM30181A
- Biweekly Oral Paclitaxel
- Increased Efficacy & Reduced Toxicity
KR Phase I/II
  • Aug. 2004. Preclinical started
  • Jan. 2006. KR IND submitted
  • Aug. 2006. KR Phase I started
  • Mar. 2009. KR Phase I/II started
  • Apr. 2009. KR Phase I completed
  • Jan, 2011. KR Phase II started (gastric cancer)
OratecanTM
(Oral Irinotecan)		 - Irinotecan + HM30181A
- Daily Oral Irinotecan
- Increased Efficacy & Reduced Toxicity
KR Phase I
  • Dec. 2006. Preclinical started
  • Nov. 2007. KR IND submitted
  • Feb. 2008. KR Phase I started
  • Jan. 2011. KR Phase Ib started (colorectal cancer)
Pan-Her Inhibitor
(HM781-36B)		 - Orally active pan-Her inhibitor
- Potent activities against EGFR mutant cells
KR Phase I
  • Dec. 2007. Preclinical started
  • Jun. 2009. KR IND submitted
  • Aug. 2009. KR Phase I started
KX-01
(In collaboration with Kinex Pharmaceuticals)		 - Src tyrosine kinase and tubulin polymerization inhibitor
- Daily oral administration, effective for multiple carcinomas
- Indication: Gastric cancer, Prostate Cancer (CRPC), Leukemia (CML)
US Phase II
  • CRPC US Phase II
EMSI
(HM61713B) 		- EGFR mutant selective inhibitor
- Reduced side effects
 
  • May. 2011. Preclinical started
    Dec. 2011. KR IND planned